Análisis de la intensidad competitiva de las ligas ACB, LEB ORO y LEB PLATA.

Con la realización de este trabajo se pretende entender aspectos relacionados entre la Economía y el Deporte. Específicamente, se aplica a medir la intensidad competitiva en las ligas profesionales del baloncesto español en las últimas 5 temporadas. El análisis realizado aplicando diversos índices y parámetros estadísticos puede ser de utilidad no solo para los aficionados sino también para los clubes, patrocinadores y empresas relacionadas con el sector. Tras una breve explicación del funcionamiento de las 3 ligas principales, ACB, LEB ORO y LEB PLATA, se exponen los métodos analíticos utilizados, Índices de Concentración, de Herfindhal y de Gini con su expresión gráfica a través de las Curvas de Lorenz. Se analizan los resultados obtenidos para cada una de las ligas y finalmente se comparan mediante varios modelos estadísticos. Los resultados obtenidos avalan la alta competitividad en las 3 ligas a la vez que no existe un líder dominante

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

UDHEBRONTo explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3.25 [3.5-4.21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases. Twenty-two patients (38.6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0.0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0.0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0.013), mainly due to terminally differentiated (TD) (p=0.034) and effector memory (EM) (p=0.031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0.029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0.10% closely associated with higher AIAE risk (Odds ratio [OR]: 5.91, 95% CI: 1.83-19.10, p=0.004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0.1% even predicted more accurately the risk of AIAEs (OR: 11.67, 95% CI: 2.62-51.89, p=0.0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058). A PB/PC percentage <0.1% at baseline identifies MS patients at low risk of secondary autoimmunity during alemtuzumab treatment.